Related Experiment Videos

Imipenem-cilastatin monotherapy in severe infections accompanying hematological malignancies

A Urabe1, F Takaku, H Mizoguchi

  • 1Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.

Japanese Journal of Medicine
|September 1, 1991
PubMed

Insights

Imipenem-cilastatin effectively treated severe infections in hematological malignancy patients with low white blood cell counts. This antibiotic monotherapy demonstrated significant efficacy against both Gram-positive and Gram-negative bacteria.

Area of Science:

  • Infectious Diseases
  • Hematology
  • Pharmacology

Background:

  • Patients with hematological malignancies often experience severe infections.
  • Granulocytopenia and neutropenia increase susceptibility to serious bacterial infections.

Purpose of the Study:

  • To evaluate the efficacy of imipenem-cilastatin in treating severe infections in patients with hematological malignancies.
  • To assess the effectiveness of imipenem-cilastatin monotherapy in neutropenic patients.

Main Methods:

  • Imipenem-cilastatin was administered at doses of 1 to 4 g/day.
  • Patients had severe infections accompanying granulocytopenia.
  • Efficacy was assessed for monotherapy and as a first-choice treatment.

Main Results:

  • Imipenem-cilastatin monotherapy was effective in 62.1% of patients.
  • Efficacy was observed even in severely neutropenic patients.
  • As a first-choice therapy, efficacy reached 73.3% for imipenem-cilastatin.
  • Both Gram-positive and Gram-negative infections were treatable.

Conclusions:

  • Imipenem-cilastatin is an effective monotherapy for severe infections in patients with hematological malignancies.
  • Early administration as first-choice therapy improves outcomes.
  • The drug demonstrates broad-spectrum activity against common pathogens in this patient population.

Related Concept Videos